Switch theme
Sign up to access all valuation multiples
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
2011
265
LTM Revenue $71.6M
LTM EBITDA n/a
-$8.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ADC Therapeutics has a last 12-month revenue of $71.6M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, ADC Therapeutics achieved revenue of $70.8M and an EBITDA of -$103M.
ADC Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ADC Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $69.6M | $70.8M | XXX | XXX | XXX |
| Gross Profit | $205M | $67.0M | XXX | XXX | XXX |
| Gross Margin | 295% | 95% | XXX | XXX | XXX |
| EBITDA | -$146M | -$103M | XXX | XXX | XXX |
| EBITDA Margin | -210% | -145% | XXX | XXX | XXX |
| Net Profit | -$156M | -$240M | XXX | XXX | XXX |
| Net Margin | -224% | -339% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, ADC Therapeutics's stock price is $1.
ADC Therapeutics has current market cap of $120M, and EV of -$8.0M.
See ADC Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$8.0M | $120M | XXX | XXX | XXX | XXX | $-1.62 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, ADC Therapeutics has market cap of $120M and EV of -$8.0M.
ADC Therapeutics's trades at -0.1x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate ADC Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for ADC Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$8.0M | XXX | XXX | XXX |
| EV/Revenue | -0.1x | XXX | XXX | XXX |
| EV/EBITDA | 0.1x | XXX | XXX | XXX |
| P/E | -0.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpADC Therapeutics's NTM/LTM revenue growth is 8%
ADC Therapeutics's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.7M for the same period.
Over next 12 months, ADC Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate ADC Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for ADC Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -145% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -30% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -136% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 30% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 91% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 155% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 275% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ADC Therapeutics acquired XXX companies to date.
Last acquisition by ADC Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . ADC Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was ADC Therapeutics founded? | ADC Therapeutics was founded in 2011. |
| Where is ADC Therapeutics headquartered? | ADC Therapeutics is headquartered in United States of America. |
| How many employees does ADC Therapeutics have? | As of today, ADC Therapeutics has 265 employees. |
| Who is the CEO of ADC Therapeutics? | ADC Therapeutics's CEO is Mr. Ameet Mallik. |
| Is ADC Therapeutics publicy listed? | Yes, ADC Therapeutics is a public company listed on NYS. |
| What is the stock symbol of ADC Therapeutics? | ADC Therapeutics trades under ADCT ticker. |
| When did ADC Therapeutics go public? | ADC Therapeutics went public in 2020. |
| Who are competitors of ADC Therapeutics? | Similar companies to ADC Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of ADC Therapeutics? | ADC Therapeutics's current market cap is $120M |
| What is the current revenue of ADC Therapeutics? | ADC Therapeutics's last 12-month revenue is $71.6M. |
| What is the current EV/Revenue multiple of ADC Therapeutics? | Current revenue multiple of ADC Therapeutics is -0.1x. |
| What is the current revenue growth of ADC Therapeutics? | ADC Therapeutics revenue growth between 2023 and 2024 was 2%. |
| Is ADC Therapeutics profitable? | Yes, ADC Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
